Researchers have identified a link between amyloid plaques and dysfunctional neuronal conduction in animal models of Alzheimer’s disease (AD). Their study, which was published in the Dec. 1, 2022, issue of Nature, suggests new ways to think about AD, as well as badly needed potential alternatives to plaque removal to fight the disease. Read More
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The transposition of DNA elements triggers an inflammatory response involved in the survival of cancer cells, a mechanism that could be blocked applying reverse transcriptase inhibitors, a class of drugs better known as anti-HIV medications. Read More
Researchers from Jecho Laboratories Inc. and Shanghai Jiao Tong University reported the discovery of a novel anti-PD-L1/CXCR4 bispecific nanobody, BsNb PX-4, being developed for the treatment of cancer. Read More
Investigators at West China Hospital, Sichuan University and affiliated organizations have discovered a novel c-Myc inhibitor being developed as a potential anticancer agent. Read More
Ischemic stroke comprises about 87% of stroke incidence. The nuclear factor κ B (NF-κB) cascade is a major regulatory pathway of inflammation and is activated in response to ischemic stroke in humans and in rodents during middle cerebral artery occlusion (MCAO). Read More
Onxeo SA has expanded its pipeline of drug candidates with OX-425, an optimized new compound of the OX-400 series sourced from its proprietary Platon platform. Read More
Biogen Inc. and C4 Therapeutics Inc. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising a degradation signaling moiety such as E3 ubiquitin ligase-binding moiety covalently linked to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of leukemia and lymphoma, multiple sclerosis, atopic dermatitis, rheumatoid arthritis and systemic lupus erythematosus. Read More
Kymera Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety reported to be useful for the treatment of cancer. Read More
Mast cells (MCs) are tissue-resident immune cells and are responsible for allergic and inflammatory processes. One potential approach for targeting MCs is to engage inhibitory receptors that can silence MC activation, such as sialic acid-binding immunoglobulin-like lectins (siglecs). Siglec-6 is an inhibitory receptor expressed on human MCs and represents an attractive therapeutic target for this purpose. Siglec-6 engagement with a monoclonal antibody (MAb) was recently shown to inhibit MC activation in vitro. Read More
Vigil Neuroscience Inc. has synthesized triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson's, Alzheimer's and Nasu-Hakola diseases. Read More
Gilgamesh Pharmaceuticals Inc. has divulged tryptamines acting as 5-HT2A receptor agonists reported to be useful for the treatment of mood disorders. Read More
Quantbiores A/S has discovered peptides acting as spike glycoprotein (S) (SARS-CoV-2)/ACE2 interaction inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19). Read More
